Home / 2020 / October / 28

Daily Archives: October 28, 2020

Skoll Foundation Funds Sabin Vaccine Institute, Dalberg and JSI Research & Training Institute, Inc. to Establish COVID-19 Vaccine Equity Project

WASHINGTON, Oct. 28, 2020 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute (Sabin) today announced that it has partnered with Dalberg and JSI Research & Training Institute, Inc. (JSI) to create the COVID-19 Vaccine Equity Project (vaccineequity.org). This collaboration will support low- and middle-income country immunization professionals in leading the equitable delivery of COVID-19 vaccines through their national immunization programs and complements the approach outlined in the COVAX Facility, the vaccines pillar of the Access to COVID-19 Tools Accelerator (ACT-A) led by the World Health Organization (WHO); Gavi, the Vaccine Alliance (Gavi); and the Coalition for Epidemic Preparedness Innovations (CEPI).

The Skoll Foundation is supporting the creation of the COVID-19 Vaccine Equity Project through start-up funding of $1 million to pilot the program in four countries. Following a successful pilot, the partners hope to secure additional funding to scale the project to more than 40 countries starting in 2021.

As COVID-19 vaccine developers generate clinical evidence of safety and effectiveness needed for vaccine approval, this project will help prepare for the efficient and equitable distribution of vaccines globally by ensuring that national immunization programs have the resources and health systems in place to achieve sustainable global protection from COVID-19 by 2022 and strengthen capacity for vaccination across the life span.

This project leverages the three partners’ global reach and decades of experience in immunization systems strengthening to facilitate national planning. Sabin builds on more than 20 years promoting equitable vaccine access through its programming, particularly the Boost Community; the collaborative and engaged network of more than 1,000 immunization professionals from more than 115 countries across the world. The Boost Community will invite its members to participate in an advisory group and interactive discussions for the COVID-19 Vaccine Equity Project in order to ensure that they are closely involved in decision making. The Dalberg team leverages its data capabilities, patient-centered approach and extensive experience assisting countries’ response efforts. Dalberg provided support to Emergency Operation Centers during the 2013-2015 Ebola outbreak in West Africa and throughout the COVID-19 pandemic, and is currently tapping into its vast global network, such as the Centers for Disease Control and Prevention in Africa, to strengthen COVID-19 response efforts. Finally, JSI provides the technical support and strategic planning needed to scale the project for global impact, leveraging the organization’s presence in more than 45 countries and deep experience assisting countries in introducing new vaccines and strengthening existing immunization programs.

“Vaccines don’t deliver themselves. Their ability to control the pandemic will depend on the strength of vaccination programs and ultimately, on the dedicated personnel who will lead these programs,” said Dr. Bruce Gellin, president of Global Immunization at Sabin. “Connecting global experts with immunization professionals who are leading on the frontlines, will provide the much needed two-way flow of data, insights and information to inform equitable vaccine delivery. We are grateful to the Skoll Foundation for recognizing the critical role immunization professionals will play in helping the world overcome this pandemic.”

The COVID-19 Vaccine Equity Project will comprise three phases designed to rapidly assess vaccine distribution landscape, maximize learnings and scale a successful pilot to enable equitable global delivery of vaccines. The Skoll Foundation is funding Phases 1 and 2. In Phase 1 (“Plan”), the group will collaborate with Sabin’s Boost Community members to coordinate with ACT-A and select the four countries in which to pilot the project. In Phase 2 (“Pilot”), all three partners will work hand-in-hand with national and subnational immunization professionals to analyze the pilot countries’ needs regarding vaccine financing, procurement and distribution; leading to the creation of tailored action plans for equitable delivery of COVID-19 vaccines. As additional funders join the project, these action plans will serve as a blueprint for Phase 3, in which a successful pilot will be scaled to more than 40 countries and expanded beyond COVID-19 vaccines to strengthen life-course immunization; an approach that prioritizes timely and effective vaccination throughout the lifespan.

“Lessons learned from previous pandemic response efforts, such as those for Ebola and H1N1, show us that one of the most effective, efficient and equitable ways to serve population needs and save lives is to take a community-centered approach and mobilize country support beyond procurement,” said Edwin Macharia, global managing partner at Dalberg. “Dalberg is energized to join this core team alongside Sabin and JSI to develop vaccine strategies using a people-centered approach and move the needle closer to a more inclusive and sustainable world.”

“This project aligns with JSI’s guiding mission to build stronger health systems to improve health outcomes for all,” said Lora Shimp, technical director at JSI’s Immunization Center. “Vaccines are a gateway to health equity and a tool to relieve a burden on stretched health systems by ensuring populations are protected against deadly or life-altering diseases. The JSI team looks forward to leveraging the technical capacity of the Immunization Center to ensure the successful scale up of this vaccine equity program across the globe.”

Phases of the project will accelerate equitable distribution now, before a vaccine arrives, to ensure that it reaches the most vulnerable among us when one becomes available. No one is safe from the virus until everyone is safe.

About the Sabin Vaccine Institute
The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with more than two decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on Twitter, @SabinVaccine.

About Dalberg
Dalberg is a leading social impact advisory group that brings together strategy consulting, design thinking, big data analytics, investment, and research to address complex social and environmental challenges. We work collaboratively with communities, institutions, governments, and corporations to develop solutions that create impact at scale and build a more inclusive and sustainable world where all people, everywhere, can reach their fullest potential.

About John Snow Research & Training Institute, Inc.
JSI Research & Training Institute, Inc. is a nonprofit global public health consulting and research organization and a global leader in strengthening routine immunization systems as well as new vaccine introductions. JSI is dedicated to improving the health of individuals and communities throughout the world. Our mission is to improve the health of underserved people and communities and to provide a place where people of passion and commitment can pursue this cause.

About the Skoll Foundation
The Skoll Foundation catalyzes transformational social change by investing in, connecting, and championing social entrepreneurs and other change leaders who together advance equitable solutions to the world’s most pressing problems.

Jeff Skoll, the first employee and first President of eBay, created the Skoll Foundation in 1999 to pursue his vision of a sustainable world of peace and prosperity for all. The Skoll Foundation is part of the Jeff Skoll Group, which also includes Participant and the Capricorn Investment Group. The Foundation is led by CEO Don Gips.

The Skoll Foundation is at an exciting inflection point in its two-decade long history. With equity at the center of an evolving strategy that extends beyond its traditional focus on social entrepreneurship, the Foundation aspires to fundamentally shift the trajectory on urgent global problems including pandemics and global health systems, racial justice, climate change, effective governance, and inclusive economies. The Foundation does this by connecting social entrepreneurs and other change leaders around the world, investing in their solutions, and championing their work.

Learn more at skoll.org.

Media Contact:
Samia Kemal
Sabin Vaccine Institute
+1 (202) 621-1691
press@sabin.org

Lotame Unveils Panorama ID, the First Global Cookieless Identity Solution for a Privacy-First Open Web

New cookieless ID powers relevant & responsible omnichannel advertising, while empowering consumers with a universal and persistent opt-out across every digital touchpoint, browser & device

NEW YORK, Oct. 28, 2020 (GLOBE NEWSWIRE) — Lotame (www.lotame.com), the leading global provider of data enrichment solutions to drive customer insights and turn personas into addressable advertising, today announced the launch of Lotame Panorama ID, the first global, people-based identity solution for a cookieless open web. Powered by Lotame’s patented graphing technology, its identity solution connects all types of device identifiers, associated individual behaviors, and privacy choices into a single view, without dependence on cookies.

Panorama ID is freely accessible to all digital advertising players and interoperable across the ecosystem via API, prebid and inbound/outbound server-to-server.

“Third-party targeting challenges and mounting privacy regulations have created an identity crisis in digital,” said Andy Monfried, CEO of Lotame. “Without privacy-friendly and people-based tools, brands and publishers can’t communicate and transact effectively in a cookieless world. If they can’t get identity right, they can’t understand or engage audiences at scale, affecting everything from customer loyalty to sales and revenue to the viability of business tomorrow. With our Panorama ID, we’re giving the marketplace equal opportunity to compete, improve consumer relationships, and deliver outstanding, diverse, ad-supported content across the open web and connected devices.”

Finding a solution to identity is pivotal for the survival of the digital ecosystem, outside the bounds of Google, Facebook and Amazon. The IAB’s Socioeconomic Impact of Internet Tracking February 2020 report found that if digital tracking ended without a replacement, “there would be a shift of between $32 billion and $39 billion of advertising from the open web to the walled gardens by 2025.”1

Created for the open web, Lotame Panorama ID is the only global identity solution built from multiple inputs, including deterministic data like customer IDs and emails, and publicly available web data. It is the first and only omnichannel and freely accessible identity solution that does not depend on third-party cookies to target consumers globally.

With this identity solution, marketers and publishers can:

  • Protect consumer privacy: Lotame Panorama ID will incorporate a universal opt-out — consumers will opt out once and that choice is reflected in real-time, persisting across every digital touchpoint, device and instance of identity. Lotame Panorama ID is compliant with GDPR, CCPA, LGPD, and adheres to IAB Transparency and Consent Framework 2.0, while setting new benchmarks for consumer privacy.
  • Increase ad targeting accuracy and scale: By matching attributes across devices and domains to an individual, and with an open ecosystem approach of more than 90 platform partners, plus data from 180 providers in 58 countries, the Lotame Panorama ID leverages the most comprehensive collection of data points in the industry to accurately triangulate the right consumer for the right message. The ID features an average of 119 web and 89 mobile attributes per pseudonymous individual, delivering the highest accuracy, profile depth, and scale across the open web.
  • Effectively measure campaigns: Lotame Panorama ID is a people-based metric that enables publishers and marketers to effectively target, measure, and deliver campaign reporting based on unique people rather than the unstable cookie ID or the threatened mobile ad ID.
  • Frequency cap by individual: In some instances, a single ad can reach a user 40 times in a month2, creating over-exposure that pushes the boundaries of acceptability for consumers. With Lotame Panorama ID, advertisers and publishers can now control how many times an individual — not a device — sees an ad across every digital touchpoint, device, and instance of their experience. This helps safeguard brand reputation for marketers, while ensuring a positive experience for inventory holders.
  • Work together: To enable relevant, responsible, and resilient advertising on an individual level, marketers and publishers need to work together to future proof their businesses. Lotame Panorama ID provides a common language for the ecosystem and an interoperable bridge for everything from ad targeting and delivery to analytics, optimization, and attribution.
  • Increase revenue beyond contextual targeting: Publishers can use Lotame Panorama ID to access previously invisible audiences across browsers and see their rich multidimensional attributes and behaviors even on the first impression. They can go beyond the limits of contextual targeting to help marketers reach customers who have qualified for audiences based on their expressed passions, behaviors, and interests across all their devices and publisher domains, as well as outside of owned properties. This unlocks valuable new monetization opportunities for publishers as COVID-19 continues to impact revenue.

Lotame Panorama ID adheres to the principles set forth by the Partnership for Responsible Addressable Media, of which Lotame is a member alongside P&G, Unilever, Ford, GM, IBM, NBCUniversal, IPG, Publicis, and digital advertising leaders.

To learn more about how Lotame Panorama ID builds a connected digital advertising ecosystem for all, please visit www.lotame.com/panorama/id

About Lotame
Lotame is the leading provider of data enrichment solutions for global enterprises. Our connected and patented data technologies, curated second- and third-party data exchanges, and high-touch customer service make us the trusted choice for marketers, agencies and media companies that want to build a panoramic view of their customers and activate across the cookieless web, mobile app and OTT environments. Lotame serves its global clients with offices in New York City, Columbia MD, Argentina, London, Mumbai, Singapore and Sydney. Learn more at www.lotame.com.

Lotame and related logos are registered trademarks or trademarks owned by Lotame Solutions, Inc. in the U.S. and/or other countries. All Rights Reserved. All other trademarks and trade names are properties of their respective owners.


1 IAB, The Socioeconomic Impact of Internet Tracking, February 2020 https://www.iab.com/insights/the-socioeconomic-impact-of-internet-tracking/

2 Warc, 2019 https://www.warc.com/newsandopinion/opinion/frequency_capping_increase_efficiency_and_reduce_consumer_irritability/2996

Chris Harihar
chris@crenshawcomm.com

Bombardier to Report its Third Quarter 2020 Financial Results on November 5, 2020

MONTRÉAL, Oct. 28, 2020 (GLOBE NEWSWIRE) — Bombardier (TSX: BBD.B) will publish its financial results for the third quarter ended September 30, 2020 on November 5, 2020.

On November 5, 2020 at 8:00 a.m., EST, Éric Martel, President and Chief Executive Officer; John Di Bert, Senior Vice President and Chief Financial Officer; and Patrick Ghoche, Vice President, Corporate Strategy and Investor Relations, will hold a webcast/conference call intended for investors and financial analysts to review the company’s financial results for the third quarter ended September 30, 2020.

A live webcast of the call and relevant financial charts will be available at http://ir.bombardier.com.

Stakeholders wishing to listen to the presentation and question and answer period by telephone may dial one of the following conference call numbers:

In English: 514-392-1587, passcode: 7514406# or
1-877-395-0279, passcode: 7514406# (toll-free in North America)
+800 4222 8835, passcode: 7514406# (overseas calls)
In French: (with translation) 514-861-1381, passcode: 5206544# ou
1-877-695-6175, passcode: 5206544# (toll-free in North America)
+800 4222 8835, passcode: 5206544# (overseas calls)

The replay of this call will be available on Bombardier’s website shortly after the end of the webcast.

About Bombardier
With nearly 60,000 employees across two business segments, Bombardier is a global leader in the transportation industry, creating innovative and game-changing planes and trains. Our products and services provide world-class transportation experiences that set new standards in passenger comfort, energy efficiency, reliability and safety.

Headquartered in Montréal, Canada, Bombardier has production and engineering sites in over 25 countries across the segments of Aviation and Transportation. Bombardier shares are traded on the Toronto Stock Exchange (BBD). In the fiscal year ended December 31, 2019, Bombardier posted revenues of $15.8 billion. News and information are available at bombardier.com or follow us on Twitter @Bombardier.

Bombardier is a trademark of Bombardier Inc.

For Information

Jessica McDonald
Advisor, Media Relations
Bombardier Inc.
+1 514 861 9481
Patrick Ghoche
Vice President, Corporate Strategy and Investor Relations,
Bombardier Inc.
+1 514 861 5727

Christie introduces groundbreaking far-UVC light fixture with patented Care222 technology for UV disinfection that may be used around people

Christie CounterAct aims to reduce pathogens in commercial indoor venues

CYPRESS, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) — Christie® is pleased to announce the launch of the Christie® CounterAct™ line of commercial UV disinfection products with patented Care222® far-UVC light technology for cinemas, theme parks, museums, sports complexes and other indoor spaces. Unlike comparable products, the Christie fixture uses Ushio’s patented narrowband filtered Care222 excimer lamps that emit far-UVC 222nm light – the only UV technology shown to continuously and significantly reduce pathogens, like coronaviruses, that may also be used while people are present, when used in accordance with specified parameters. Mass production of the new Christie CounterAct fixture starts in January 2021.

Developed by Christie’s parent company, Ushio Inc., based on technology licensed from Columbia University, the revolutionary Care222 far-UVC, mercury-free excimer lamp—highlighted in FORTUNE magazine’s annual Change the World list1 in 2020, includes a proprietary short pass filter that prevents the emission of longer wavelengths of UV light (230nm and higher) that are capable of penetrating human skin and eyes, an especially important feature that other 222nm and far-UVC products do not have.

Christie CounterAct introduces an added layer of defense against pathogens in indoor venues when guests and staff are present

Christie CounterAct is a line of fixtures that are simple to control remotely and can be installed on ceilings as easily as a commercial lighting fixture. It is well suited for use across a wide range of occupied, commercial areas such as entertainment venues, including lobbies, auditoriums, and restrooms, as well as other indoor spaces. Our first Christie CounterAct fixture contains two Care222 excimer far-UVC lamps that significantly reduce pathogens on surfaces of any indoor space. The fixture, with fast instant on/off at full output power and its Care222 technology lamps, has been shown effective at reducing pathogens in laboratory tests2 . And unlike other UV technology, these fixtures with patented Care222 lamps may be used when people are present.

The background on UV light

It has been known for many years that UV light is a highly effective disinfectant that can reduce pathogens in indoor spaces. Businesses and other institutions have long used germicidal UVC light to stop the spread of viruses. The main drawback with most UVC technology is that it uses a 254nm wavelength that can penetrate human skin and eyes, which means these germicidal lights can only be used when people are not present or while they’re wearing personal protective equipment (PPE) that protects the eyes and skin. These shortcomings constrain how these devices must be operated and limit their widespread use in occupied indoor spaces.

A study3 conducted by Kobe University published in August 2020 concludes that, due to its shorter wavelength, far-UVC 222nm light does not penetrate the skin and therefore may be used when humans are present. Another recent study4 published in the American Journal of Infection Control shows that far-UVC 222nm light can effectively reduce more than 99.7% of surface contamination of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19.

Researchers at Columbia University Irving Medical Center have also tested far-UVC 222nm light, and in particular its effect on aerosolized seasonal coronaviruses (that cause the common cold). A scientific paper published by this group in the journal Nature5 in June 2020 found that 99.9% of aerosolized seasonal coronaviruses (the cause of the common cold) were inactivated when exposed to far-UVC 222nm light in just 25 minutes.

These studies’ findings suggest that the filtered 222nm far-UVC light emitted by Care222 lamps in Christie’s CounterAct fixture, which can operate continuously even when people are present, offers a significant improvement over traditional manual cleaning alone, which requires professional cleaners, and the repeated use of harsh chemicals, in which the results are temporary.

Zoran Veselic, president and COO, Christie, added: “People are essential to the entertainment industry, and their level of comfort in public venues is paramount to the industry’s success.We are very proud to be able to offer this product with Ushio’s Care222 technology to our partners, and we are excited about the possibilities the technology will have in bringing customers back to the places they love, such as movie theaters and theme parks. The fact that far-UVC light – specifically, our new Christie CounterAct far-UVC fixture – can be used in the presence of people is a real differentiating factor. By harnessing these benefits as part of a user-friendly product that can be quickly deployed, we hope to provide a much-needed boost to our partners across the entertainment industry who are currently struggling to attract wary customers.”

For more information visit Christie’s CounterAct website.

-30-

1. FORTUNE Magazine’s Change the World highlights Ushio’s achievements in developing Care222® filtered Far UV-C disinfection modules, and the research being conducted in collaboration with Japan’s Kobe University and Columbia University. Represented at number 40, Ushio stands alongside other companies that demonstrate measurable social impact and innovations within their industries by pioneering new technology or services.

2. The pathogen-reducing efficacy of Christie CounterAct products with patented Care222 technology and their use in occupied spaces is dependent on proper installation and operational specifications, in accordance with the American Conference of Governmental Institutional Hygienist (ACGIH) guidelines. Link to ACGIH

3. Fukui T, Niikura T, Oda T, Kumabe Y, Ohashi H, et al. (2020) Exploratory clinical trial on the safety and bactericidal effect of 222-nm ultraviolet C irradiation in healthy humans. PLOS ONE 15(8): e0235948. Link to report

4. Kitigawa H, Nomura T, Nazmul T, Shigemoto N, Sakaguchi T, Ohge H, et al. (2020) Effectiveness of 222-nm ultraviolet light on disinfecting SARS-CoV-2 surface contamination. American Journal of Infection Control. Link to report

5. Buonanno, M., Welch, D., Shuryak, I. et al. (2020) Far-UVC light (222 nm) efficiently and safely inactivates airborne human coronaviruses. Sci Rep 10, 10285. Link to report

Notes:

Christie CounterAct products with patented Care222 technology are not for use on humans or animals or to disinfect medical devices.

The pathogen-reducing efficacy of Christie CounterAct products with patented Care222 technology and their use in occupied spaces is dependent on proper installation and operational specifications, in accordance with American Conference of Governmental Industrial Hygienists (ACGIH) guidelines.

Any references to “disinfection” and “disinfecting” are referring generally to the reduction of pathogenic bioburden and are not intended to refer to any specific definition of the term as may be used for other purposes by the U.S. Food and Drug Administration or the U.S. Environmental Protection Agency.

About Christie

Christie Digital Systems USA, Inc. is a global visual and audio technologies company and a wholly owned subsidiary of Ushio Inc., Japan (JP: 6925). Christie revolutionized the movie industry with the launch of digital cinema projection, and since 1929 has embraced innovation and broken many technology barriers. From the world’s largest mega-events to the smallest applications, our technology—from advanced RGB pure laser and SDVoE technology to image processing and LED display solutions—empowers people to create the world’s best shared experiences. Visit www.christiedigital.com.

Follow Christie:

https://twitter.com/christiedigital
https://www.facebook.com/christiedigital/
https://www.facebook.com/christiecinemasolutions/
https://www.linkedin.com/company/christie-digital-systems
https://www.youtube.com/christiedigital
https://www.instagram.com/christiedigital/
https://vimeo.com/christiedigital

All trademarks referenced are property of their respective owners.

“Christie” is a trademark of Christie Digital Systems USA, Inc., registered in the United States of America and certain other countries.

The Care222 standard character mark and stylized logo mark are registered trademarks of Ushio America, Inc., in the United States, European Union, United Kingdom, and Japan.

Attachments

Carmen Robert
Christie
519-593-3588
carmen.robert@christiedigital.com

SAFR® from RealNetworks Launches Version 3.0 Featuring Enhanced COVID-19 Response Features and a New High Sensitivity Face Detector

Sets a new standard for face detection when wearing PPE

SAFR 3.0

SAFR recognizes a registered face, even when wearing a face mask.

SEATTLE, Oct. 28, 2020 (GLOBE NEWSWIRE) — SAFR from RealNetworks, Inc. (NASDAQ: RNWK) today announced improved face detection and recognition accuracy for both masked and unmasked faces with the release of SAFR 3.0. Available now, SAFR’s 3.0 release introduces a new default high sensitivity face detector. Customers running the high sensitivity face detector will see a 95.1% detection rate and 98.85% recognition accuracy rate for faces covered by PPE face masks — including non-surgical fabric masks of varying patterns — in surveillance-style videos of faces in motion. Detection efficiency has also been improved when multiple faces are simultaneously in the field of view to ensure detection and recognition speeds remain high.

“With the 3.0 release, SAFR continues its track record of maintaining high-accuracy under challenging real-world conditions, including the new norms brought by this global pandemic. SAFR’s accuracy improvements will enable customers to deploy face-based contactless secure access without requiring removal of PPE and ensure persons of interest and registered VIPs don’t go unrecognized while wearing face masks,” said Brad Donaldson, VP Computer Vision, SAFR.

SAFR 3.0 also includes a new mask detection dashboard that enables customers to anonymously track mask usage rates and view and filter by age, gender, location, and time. This dashboard joins the existing occupancy and traversal dashboards available in the SAFR web console.

“NTT DOCOMO provides facial recognition service with RealNetworks to the Japanese market. With SAFR’s new functionalities, and in particular the new mask detection feature, we believe that we can enhance the safety and security of people and organizations. We will continue to work with various partners to create new value-added solutions to help solve social issues,” said Hisakazu Tsuboya, Senior Vice President, General Manager of 5G & IoT Business Department, NTT DOCOMO, INC.

Learn more about the 3.0 release at https://safr.com/release-notes/.

About SAFR
SAFR (www.safr.com) is the world’s foremost facial recognition platform for live video intelligence. It taps the power of AI to help the world get back to work. Whether it’s used for occupancy counting, face mask detection, or touchless entry control, SAFR can be deployed on premises, in the cloud, or with a VMS. SAFR enhances security, heightens situational awareness, and delivers insights that improve operational efficiency and protect the health and safety of people everywhere.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f20caff2-d570-4f50-89b1-2fd7993061c1

For more information please contact:
Amanda Perry
Public_relations@realnetworks.com

Trip.com partners with Bangkok Airways FlyerBonus

Trip.com x Bangkok Airways FlyerBonus

Trip.com x Bangkok Airways FlyerBonus

SINGAPORE, Oct. 28, 2020 (GLOBE NEWSWIRE) — Trip.com, a leading international online travel service provider with over 1.4 million properties in more than 200 countries and regions, today announced a partnership with Bangkok Airways’ frequent flyer programme, FlyerBonus which will maximize rewards for its members when making hotel reservations on Trip.com.

As part of the partnership, FlyerBonus members will earn 10 FlyerBonus points per US$3 (or currency equivalent) excluding taxes and fees.spent when they book their stay with Trip.com at www.trip.com/w/flyer-bonus or th.trip.com/w/flyerbonus, and have access to some of the best deals on over 1.4 million properties in over 200 countries and regions, including from business hotels, airport hotels, train station hotels, luxury hotels and resorts.

Understanding that flexibility during these times is important, Trip.com provides customers special discounts or free cancellation guarantee on advance reservations.

“As travelers around the world look towards their next trips, we are delighted to collaborate with FlyerBonus by Bangkok Airways to enhance FlyerBonus members’ travel experience and prepare for the travel recovery in Southeast Asia,” said Bo Sun, Trip.com Group Chief Marketing Officer.

Mr. Chulin Korcharoen, Vice President – Sales and Acting Vice President – Marketing of Bangkok Airways said, “We are very pleased to partner with Trip.com, one of the world’s leading online travel platforms. We believe that this partnership will help enhance our travelers journey to be more delightful as travelers can now quickly gain FlyerBonus points when booking their trip on www.trip.com/w/flyer-bonus.

To take advantage of this launch offer and start earning FlyerBonus points with Trip.com, FlyerBonus members must book a hotel stay via our the dedicated landing page at www.trip.com/w/flyer-bonus or th.trip.com/w/flyerbonus The FlyerBonus points will be credited to your account within 12 weeks after the completion of stay.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/eaa0cba7-70eb-450f-a3e7-0bc9d6aee7f7

Trip.com Rep Details 
For further information, please contact
Trip.com PR
pr@trip.com
Tel: (+86) 21 3406 4880 ext 196455

SweeGen Commercializes New Bestevia® Reb I

FDA GRAS and FEMA GRAS achieved.

Rancho Santa Margarita, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) — As clean-label zero-calorie natural sweeteners continue to be attractive to consumers, SweeGen announced the expansion of its natural sweetener portfolio with the commercial production of Bestevia® Reb I, a next generation high-purity stevia sweetener and flavor unique to SweeGen.

Reb I expands SweeGen’s toolbox for tackling the challenges of reducing sugar and delivering sweet taste solutions to food and beverage manufacturers. This newest edition to SweeGen’s natural sweetener portfolio works well in product applications across the spectrum, ranging from dairy, beverages, nutritional bars, confectionery to savory.

“Reb I is yet another unique and diverse flavor that we can use in our creative building block approach to sugar reduction for creating consumer-preferred sugar-reduced food and beverage products, and delivering winning solutions to our clients,” said Chief of Global Flavor Application Technology, Shari Mahon.

Reb I imparts a clean taste profile and sugar-like sweetness and complements SweeGen’s application technology. It is a versatile sweetener which can be used at various levels of sugar reduction to drive unique taste profiles.

Reb I is produced by a patented bioconversion technology, starting with the stevia leaf. This process was developed by Conagen, a biotech innovator of sustainable ingredients. SweeGen’s entire proprietary portfolio of next generation, natural Bestevia stevia sweeteners are produced with Conagen’s bioconversion technology, and are classified as next generation non-GMO, high-purity, and clean tasting. The Bestevia portfolio includes Rebs B, D, E and M, and now Reb I. These Rebs translate to highly-relevant clean-label, sustainable, natural sweeteners that consumers seek.

More than 66% of consumers prefer to see natural sweeteners rather than artificial on labels. This trend drives brands to search for solutions in the natural sweetener and plant-based spaces which now includes Bestevia Reb I.

SweeGen has already received the FDA Generally Regarded As Safe (GRAS) no objection letter, and achieved The Flavor and Extract Manufacturers Association (FEMA). Global regulatory approval is underway.

“Conagen is happy to support the successful commercialization of Reb I as the latest offering from our pipeline of non-caloric sweeteners.  We are looking forward to additional unique and novel stevia sweeteners for providing greater flexibility and options to food and beverage manufacturers,” said Conagen’s VP of Innovation, Dr. Casey Lippmeier.

About SweeGen

SweeGen provides sweet taste solutions for global food and beverage manufacturers.

We are on a mission to reduce the sugar and artificial sweeteners in our global diet.  Partnering with customers, we create delicious zero-sugar products that consumers love.  With the best next generation stevia sweeteners in our portfolio such as Bestevia® Rebs B, D, E, I and M, along with our deep knowledge of flavor modulators and texturants, SweeGen delivers market-leading solutions that customers want and consumers prefer.

For more information please contact info@sweegen.com and visit SweeGen’s website, www.sweegen.com.

About Conagen

Conagen is making the impossible possible. Our scientists and engineers are bettering humankind and the world by employing advanced synthetic biology tools for the bioproduction of high-value ingredients for food, nutrition, flavor and fragrance, pharmaceutical, and renewable materials industries. www.conagen.com

Cautionary Statement Concerning Forward-Looking Statements
This press release contains forward looking statements, including, among other statements, statements regarding the future prospects for Rebs, B, D, E, I and M stevia leaf sweeteners. These statements are based on current expectations, but are subject to certain risks and uncertainties, many of which are difficult to predict and are beyond the control of SweeGen, Inc.

Relevant risks and uncertainties include those referenced in the historic filings of SweeGen, Inc. with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from those expressed in or implied by the forward-looking statements, and therefore should be carefully considered. SweeGen, Inc. assumes no obligation to update any forward-looking statements as a result of new information or future events or developments.

Attachment

Ana Arakelian
SweeGen, Inc.
949-709-0583
ana.arakelian@sweegen.com